Glenmark Pharmaceuticals USA launches Clindamycin Phosphate Foam, 1%
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
India Business grew by 11.9% YoY to Rs. 1196.2 crore
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
European operations' revenue grew 58.4% to Rs 599.7 crore
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
The company has entered into a three-year Deferred Prosecution Agreement
Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace
Subscribe To Our Newsletter & Stay Updated